Piramal Pharma Limited reported robust financial results for the first quarter of FY27 (ended June 30, 2026). The company saw a 17% increase in Revenue from Operations to ₹2,270 crore. EBITDA surged by 72% to ₹285 crore, with EBITDA margin expanding to 12.5%. All three business segments—CDMO, CHG, and PCH—contributed to this strong performance, with significant growth noted across the board.
Piramal Pharma Limited Q1 FY27 Results Unveiled
Piramal Pharma Limited has announced its standalone and consolidated financial results for the first quarter (Q1) of the fiscal year 2027, which concluded on June 30, 2026. The company has demonstrated a strong start to the fiscal year, driven by healthy revenue growth and significant margin expansion across its diverse business segments.
Consolidated Financial Highlights
In the first quarter of FY27, Piramal Pharma Limited achieved a total Revenue from Operations of ₹2,270 crore, marking a 17% increase compared to ₹1,934 crore in Q1 FY26. The company’s EBITDA saw a substantial rise of 72%, reaching ₹285 crore in Q1 FY27 from ₹165 crore in the same period last year. Consequently, the EBITDA margin improved significantly to 12.5% from 8.5% in Q1 FY26, an expansion of 400 basis points.
Performance Across Business Segments
The company’s performance was bolstered by strong contributions from its three core businesses:
- CDMO (Contract Development and Manufacturing Organization): Revenue from this segment grew by 19% to ₹1,187 crore. This growth was attributed to broad-based performance across India and overseas sites, healthy order inflows, and improved win rates, supported by an enhanced commercial team.
- CHG (Complex Hospital Generics): CHG reported a revenue increase of 17%, reaching ₹743 crore. Key highlights include sustained leadership in the US Sevoflurane market and progress in ex-US markets, alongside the upcoming launch of Kenalog® supplies in Q2FY27.
- PCH (Piramal Consumer Healthcare): This segment registered a 15% revenue growth, with sales amounting to ₹347 crore. The growth was driven by Power Brands (up 23% YoY) and a 40% YoY increase in e-commerce sales.
Key Strategic Updates and Outlook
Nandini Piramal, Chairperson of Piramal Pharma Limited, expressed optimism about the company’s trajectory, stating, “We have started FY27 on a strong note, with all three businesses delivering mid-to-high teens revenue growth alongside meaningful EBITDA margin expansion.” The company highlighted its focus on superior execution, improved utilization, pricing discipline, and operational excellence as drivers for margin expansion. Furthermore, the Sellersville facility in the US received an Establishment Inspection Report from the US FDA, maintaining its Zero OAI status.
Piramal Pharma Limited anticipates building on this momentum throughout FY27, aiming for sustained revenue growth and profitability expansion while adapting to a dynamic external environment.
Source: BSE
